Communiqués Iovance Biotherapeutics, Inc. Deutsche Boerse AG

Actions

2LB

US4622601007

Recherche biotechnologique et médicale

Marché Fermé - Deutsche Boerse AG 14:50:12 06/10/2026			Après clôture 22:00:57
12,52 ^EUR	+0,97%		11,55	-7,75%

01/10	Iovance Biotherapeutics annonce la nomination de Noah Berkowitz au poste de directeur médical, à compter du 30 septembre 2026	CI
29/09	Les actions d’Iovance Biotherapeutics bondissent après le relèvement des prévisions de chiffre d’affaires pour 2026	MT

Communiqués

01/10	Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	AQ
29/09	Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million	AQ
21/09	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
18/09	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
04/09	Iovance Biotherapeutics to Present at Upcoming Conferences	AQ
24/08	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
21/08	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
06/08	Iovance Biotherapeutics: Q2 Earnings Snapshot	AQ
06/08	Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates	AQ
30/07	Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026	AQ
20/07	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	AQ
17/07	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
22/06	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
19/06	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
03/06	Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia	AQ
01/06	Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001	AQ
26/05	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 22, 2026	AQ
22/05	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
21/05	Iovance Biotherapeutics to Present at Upcoming Conference	AQ
07/05	Iovance Biotherapeutics: Q1 Earnings Snapshot	AQ
07/05	Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates	AQ
27/04	Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026	AQ
20/04	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
17/04	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
20/03	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ